FDA approved expansion Neurolief’s FDA approved Proliv Rx for adults with Major Depressive Disorder presents a clear near-term upsell path to clinics and hospitals seeking compliant, at-home brain stimulation solutions for treatment-resistant depression.

Clinical trial momentum With ongoing pivotal studies like Relivion DP and recent financing tied to FDA milestones, there is an opportunity to partner with research organizations, contract research firms, and academic medical centers to support trial recruitment and real-world evidence generation.

Strategic financing The recent $6 million investment post-FDA approval signals stronger commercial push potential; engage investors, payer strategists, and health systems to co-create reimbursement pathways and scale adoption across outpatient and telehealth channels.

Neuromodulation portfolio Neurolief’s multi-channel, non-invasive neuromodulation platform differentiates from single-channel competitors; target neurology and psychiatry groups focusing on migraine, depression, and other neuropsychiatric conditions to broaden use cases and patient reach.

Executive alignment Key leadership hires in medical and commercial roles (CMO and CCO appointments) indicate a company ready to scale; position partnerships with healthcare providers, KOLs, and distributors to accelerate market penetration and product adoption.